Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

NextGen Introduces Animal Biomarker Products for Development of Brain Disorder Diagnostics

Published: Friday, June 15, 2012
Last Updated: Friday, June 15, 2012
Bookmark and Share
Measures biomarkers in rat cerebrospinal fluid.

NextGen Group Plc has announced the commercialization of a new assay for the identification of diagnostic biomarkers in brain disorders in animal models.

The assay measures protein markers in rat cerebrospinal fluid and will expand the product offering of NextGen’s contract research subsidiary, NextGen Sciences Inc.

An assay is the procedure for measuring the effects of a chemical in an organism. For example, assays are used to discover biomarkers which are in turn used to identify the existence and progression of a disease.

Biomarkers are used in clinical trials to aid in patient selection and to evaluate the effectiveness of a drug. They are also used in the development of companion diagnostics that will drive the growth of the personalized medicine market.

There is a significant need for biomarkers to monitor and diagnose central nervous system disorders, such as dementia, Parkinson’s disease and neuropsychological disorders, within the patient care and drug development industries.

NextGen’s “CSFassay-rat A.1.0” product is capable of measuring 62 cerebrospinal fluid (CSF) proteins simultaneously that have been identified as likely biomarkers in various central nervous system (CNS) disorders.

Barry McAleer, PhD, CEO of NextGen Sciences Inc says: “Assays that can discover biomarkers in animal models will enhance the drug development process within the pharmaceutical industry and could lead to reduced attrition in the drug development process. With the introduction of the CSFassay-rat A.1.0 we have delivered on the first phase of ongoing product development plans that enables us to support and enhance the pre-clinical drug development programs of our customers. This new product and those currently in development are already attracting interest in the marketplace and we are in discussions with a number of clients who wish to use these assays in their R&D programmes.”

The release of the CSFassay-rat A.1.0 product is the first assay in a family of animal model CSF assays and provides confirmation of NextGen’s previously stated intention to deliver assays in animal species.

Explains Barry McAleer: “Our customers can choose to employ our current assay products in their diagnostic biomarker programs or they can ask us to make custom assays for them, in multiple species, in CSF and plasma and for hundreds of proteins. We can do it in just a matter of weeks.

“With our previously released human CSF and plasma assays we continue to widen the landscape for our customers to find diagnostic biomarkers in different animal species models. These biomarkers can be combined in a single assay that can be employed through the pre-clinical and clinical stages of drug development. This improves the chances for diagnostic markers to proceed all the way through to companion diagnostics and to aid the personalization of medicine.”

NextGen uses mass spectrometry (a technique for specifically identifying and quantifying biomarkers in samples) as its core technology to discover highly specific protein biomarkers that can be used for diagnostic purposes.

“The speed with which we can develop these assays (three times faster than our previous assays), in multiple species and with hundreds of analytes, signifies a huge step forward in the speed with which we can look to grow our business.”

Klaus Rosenau, Chairman of NextGen Group PLC, explains: “We continue to strengthen our position towards becoming be a leader in providing high quality diagnostic biomarker assays. We intend to increase the speed with which we can exploit our technology and products within the project engine pipeline of the NextGen Sciences Dx business. Projects are already at different stages of development as we pursue our ambition to generate further intellectual property and seek out biomarker sale/licencing/testing routes to build shareholder value.”

In 2010, the total global market for biomarkers was an estimated $13.5 billion and is expected to grow to nearly $33.3 billion by the end of 2015 (BCC Research).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

NextGen's New Diagnostics Company Established
Progress on filing of intellectual property expected in the next six months.
Monday, February 27, 2012
Scientific News
AACC 2016 Sees Clinical Chemistry Labs Drive Precision Medicine Offerings
Biomarker assays to enable precision medicine and risk assessment, mass spec-based tests designed for use in clinical labs large and small, and liquid biopsy technology captured the spotlight at the AACC annual meeting.
Diagnosing Bacterial Infections in Blood Samples
Researchers have diagnosed a bacterial infection from a blood sample in infants.
Neurodvelopmental Disorder Cause Linked to SON Gene
A genetic link has been discovered for a previously unxplained neurodevelopmental disorder.
World's Most In-Depth Study to Detect Alzheimer's Disease
A multisite team will see the most thorough and vigorous testing for Alzheimer's ever performed on volunteers.
Personalised Medicine: Dose by Design
Personalised medicine holds the promise of a new approach to healthcare, tailored exactly to our individual needs, as Congenica's Nick Lench discussed on a recent BBC Radio 4 programme.
Misdiagnosis in HCM Tests
Genetic tests for potentially fatal heart anomaly can misdiagnose condition in black Americans.
Computers Better Predict Lung Cancer Type, Severity
Study shows automating the analysis of cancer tissue samples increases the accuracy of tumor classification and patient prognoses.
Examining New Hypotheses for Undiagnosed Patients
UnDx Consortium gathers in San Diego to create new paths to identifying currently undiagnosed illnesses.
Automating Genetic Analysis
Researchers are looking to have computers help perform genetic analysis when scientists study a patient's genome to diagnose a disease.
Understanding Tumor Evolution
Study provides insight into tumor evolution; may point to improved diagnosis and treatment.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!